Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Omnicell, Inc. filings document financial results, guidance updates, governance matters, and capital-plan items for a Nasdaq-listed healthcare technology company focused on medication management. Form 8-K reports furnish quarterly and annual operating results and record material events such as executive appointments and amendments to bylaws.
Proxy materials describe annual meeting proposals, director elections, executive compensation votes, equity incentive plan authorization, certificate of incorporation amendments, auditor ratification, and related stockholder voting mechanics. These filings also provide formal disclosure around Omnicell’s common stock governance, board oversight, and stockholder rights provisions.
Omnicell, Inc. reported results of its 2026 Annual Meeting and related governance changes. Stockholders approved an amendment to the 2009 Equity Incentive Plan that adds 1,600,000 shares of common stock authorized for issuance under the plan, increasing the pool available for equity-based compensation.
Stockholders elected Joanne B. Bauer, Robin G. Seim and Eileen J. Voynick as Class I directors to serve until the 2029 Annual Meeting. They also approved, on an advisory basis, named executive officer compensation, and ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
The company amended its Amended and Restated Certificate of Incorporation to provide exculpation from personal liability for certain officers as permitted by Delaware law and to make minor non-substantive updates, following prior approval by the Board and stockholders.
Omnicell EVP and COO Nnamdi Njoku reported an open-market sale of 3,090 shares of common stock at $43.22 per share. In a separate transaction, 3,660 shares were withheld to cover taxes upon vesting of restricted stock units. After these transactions, he directly holds about 154,785 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
Omnicell, Inc. VP and Chief Accounting Officer Brian H. Nutt reported a routine tax-related share disposition. On this Form 4, 226 shares of common stock were withheld at $43.12 per share to cover taxes due upon vesting of restricted stock units. After this withholding, he directly holds 22,859.6135 shares, and there was no open-market buy or sell transaction.
OMNICELL, INC. executive Corey J. Manley, EVP and Chief Legal/Admin Officer, reported two transactions in company common stock. He sold 5,025 shares in an open-market trade at an exact price of $43.22 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. Separately, 4,041 shares were withheld to cover taxes due on vesting of restricted stock units. After these transactions, he directly holds about 112,783 common shares.
OMNICELL, INC. Chairman, President and CEO Randall A. Lipps reported a tax-related share disposition. On May 15, 2026, 12,347 shares of common stock were withheld at $43.12 per share to cover taxes due upon the vesting of restricted stock units.
After this withholding, he directly holds about 523,184.0741 shares of Omnicell common stock. He also reports indirect holdings of 8,051 shares in a trust for his children and 355,861 shares in a trust with his wife.
OMCL submitted a Form 144 notice reporting a proposed sale of 5,025 shares of Common Stock tied to restricted stock vesting on 05/15/2026. The filing lists Fidelity Brokerage Services LLC as the broker and shows shares outstanding of 45,478,909 shares as of 05/18/2026. The filing also discloses a prior sale of 7,405 shares on 03/16/2026 with proceeds of $256,879.45.
Omnicell, Inc. reported that multiple Wellington entities collectively hold 2,707,046 shares of its common stock, representing 5.96% of the class as of 03/31/2026. The filing attributes shared voting power of 1,808,062 and shared dispositive power of 2,707,046 among the reporting entities.
Omnicell, Inc. reported stronger results for the three months ended March 31, 2026, with total revenues of $309.9 million compared to $269.7 million a year earlier, driven by growth in both product and service revenues. Net income was $11.4 million, versus a net loss of $7.0 million in the prior-year period, and diluted earnings per share reached $0.25.
Operating cash flow increased to $54.5 million from $25.9 million, supporting a cash, cash equivalents, and restricted cash balance of $291.0 million and total assets of $2.0 billion. The company ended the quarter with no borrowings under its $350.0 million revolving credit facility and had $172.5 million of 1.00% Convertible Senior Notes due 2029 outstanding.
Omnicell Inc ownership disclosed: Vanguard Capital Management reports beneficial ownership of 2,274,766 shares of Omnicell common stock, representing 5% of the class. The filing shows Vanguard has sole voting power for 340,249 shares and sole dispositive power for 2,274,766 shares. The Schedule 13G is signed by Ashley Grim on 04/30/2026.